Monopar Therapeutics Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2017 to Q3 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Monopar Therapeutics quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2017 to Q3 2024.
- Monopar Therapeutics Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$1.3M, a 33.2% increase year-over-year.
- Monopar Therapeutics Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$6.47M, a 31.7% increase year-over-year.
- Monopar Therapeutics annual Net Income (Loss) Attributable to Parent for 2023 was -$8.4M, a 20.1% increase from 2022.
- Monopar Therapeutics annual Net Income (Loss) Attributable to Parent for 2022 was -$10.5M, a 15.5% decline from 2021.
- Monopar Therapeutics annual Net Income (Loss) Attributable to Parent for 2021 was -$9.1M, a 44.4% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)